Year of creation: 20
Status: SAS
Workforce: 15
% of the turnover dedicated to R&D: 90
Patents: 24

MAILING ADDRESS
Biopôle Clermont-Limagne
5 rue Emile Duclaux
63360 Saint-Beauzire
France

CONTACT
François Boutignon
President and CEO
Phone: +33 473 670 670
Email: f.boutignon@aptyspharma.com
Website: www.aptyspharma.com

APTYS PHARMA

Aptys Pharma, specialized in the design of formulations.

WHO IS APTYS PHARMA®?
Founded in 2002, Aptys Pharma® is a company specialized in formulation designpre-formulation, and analytical development.

Aptys Pharma® also offers quality control and ICH stability studies thanks to its GMP-compliant and pre-qualified WHO laboratory.

Therefore, Aptys Pharma® clients can start GMP production thanks to a ready-to-use package covering the formula and recipe, the validated analytical methods and ICH stability data.

APTYS OFFER :
Aptys Pharma® proposes different consulting and operation services to its clients, to cover most strategic phases of drug development.

Aptys preformulation expertise is completed by 2 offers: Soludiag® & Nanosolution® which have both the advantage to require low amounts of active substance and being fast.

  • Soludiag®a quick process to test the solubility of an active molecule using more than 20 different solvents and co-solvents. The amount of active molecule needed to perform this test is about 100 mg.
  • Nanosolution®a quick process to assess the conditions of nanonisation of powder with more than 40 different parameters. The amount of active molecule needed to perform this test is about 1 g.

Aptys formulation design expertise covers a wide range of dosage forms  and particularly peptide-based forms (microspheres), buccal, ocular, transdermal, and injectable forms. Formulation design also covers preclinical formulation with Soluprec®. Preclinical research requires formulations that can be used to administer high and increasing doses (dose finding).

Since 2002, Aptys have developed numerous complex dosage forms. Such as Loramyc®, a sustained release bioadhesive buccal tablet containing miconazole to treat oral candidiasis, and Testocream®, a transdermal cream containing testosterone to treat hypogonadism.

Aptys pharma® has been involved with several partners for more than 15 years in the fight against pain by developing Metapain®, an alternative to opioids and NSAIDS.

 

APTYS CLIENTS:

Aptys Pharma® works mainly with three types of customer:

– Biotech start-ups looking for the right formulation for their pre-clinical and clinical trials,

– Pharmaceutical start-ups developing new pharmaceutical forms from royalty-free molecules as part of repositioning or with the aim of improving bioavailability or compliance.

– Pharmaceutical companies that are mainly looking for cutting-edge technological expertise.

 

APTYS STRUCTURE:
Aptys has 2 laboratories:

  • a formulation design laboratory hosting equipment such as tableting machines, fluid bed granulators, granulators, freeze-dryer, homogenizers, and mixers, as well as control equipment: milling and sieving apparatus, polarized microscope, particle size analyser, halogen moisture analyser, viscosimeter, tablet hardness tester, friability tester, tap density tester, disintegration tester, pH meter.
  • a GMP-compliant, WHO-qualified analytical laboratory equipped with HPLCs & UHPLC, UV and IR spectrophotometers, GC, titrimeter, coulometer, densimeter, TLC apparatus, dissolution testing (AT7 and USP4), viscosimeter, titrator, ICH stability chambers, balances, and microbalance as well as qualified refrigerators and freezers at -20 and -80.

Also, the labs are equipped with isolators and safety cabinets to handle potent and toxic molecules (peptides, hormones, anti-cancer drugs).

APTYS STRENGTHS :
Aptys Pharma® helps Its clients to go the GMP product.  Our clients come to us because we can solve formulation problems and make from a bright idea an Industrial reality.

Moreover, Aptys Pharma® has strong expertise in the peptide-based product development to assist their clients from the design of the peptide structure to the final dosage form.